Xeris Biopharma (XERS) vs Zymeworks (ZYME)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Zymeworks (ZYME) has outperformed Xeris Biopharma (XERS) over the past year, gaining 51.4% versus a gain of 24.3%. Over five years, XERS leads with a +409.5% price change compared with -2.6% for ZYME. Xeris Biopharma is the larger company by market cap ($1.86 billion vs $1.81 billion), about 1.0 times the size.
On valuation, Xeris Biopharma trades at a lower forward P/E (27.5x vs 29.0x for Zymeworks). Xeris Biopharma converts more of its revenue into profit, with a net margin of 0.2% versus -76.6%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | XERS | ZYME |
|---|---|---|
| Share price | $10.19 | $25.26 |
| Market cap | $1.86B | $1.81B |
| 1-day change | +0.79% | -4.79% |
| YTD return | +29.81% | -4.06% |
| 1-year return | +24.27% | +51.44% |
| 5-year return | +409.50% | -2.62% |
| Forward P/E | 27.54 | 28.97 |
| EPS (TTM) | $-0.10 | $-2.02 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $291.85M | $105.97M |
| Revenue growth (YoY) | +43.72% | +38.87% |
| Net income (latest FY) | $554.00K | $-81.13M |
| Gross margin | 85.41% | — |
| Operating margin | 8.53% | -87.34% |
| Net margin | 0.19% | -76.56% |
| 52-week high | $11.33 | $31.34 |
| 52-week low | $5.25 | $16.00 |
| Distance from 52-week high | -10.06% | -19.40% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +26.20% | +63.14% |
| Average volume | 2.17M | 699.88K |
| Shares outstanding | 182.32M | 71.20M |
| Employees | 435 | 231 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ZYME has outperformed XERS by 27.2 percentage points over the past year.
- Xeris Biopharma is more profitable, keeping 0.2 cents of every revenue dollar as net income versus -76.6 cents for Zymeworks.
About Xeris Biopharma
XERS stock →Xeris Biopharma Holdings, Inc., a commercial-stage biopharmaceutical company, engages in developing and commercializing therapies for chronic endocrine and neurological diseases in Illinois. It offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia in pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome.
Health Care · Biotechnology: Pharmaceutical Preparations · 435 employees
About Zymeworks
ZYME stock →Zymeworks Inc., a biotechnology company, develops biotherapeutics for the treatment of cancer, inflammation, and autoimmune diseases. The company's platforms include Azymetric multispecific antibody platform; Drug Conjugate platform that includes a suite of proprietary cytotoxins comprising topoisomerase and microtubulin inhibiting toxins, stable linkers, and conjugation technologies; EFECT platform, which consists of a set of modifications to the Fc region of antibodies; and ProTECT, a tumor-specific immune co-stimulation platform.
Health Care · Biotechnology: Pharmaceutical Preparations · 231 employees
XERS vs ZYME FAQ
Which is bigger, Xeris Biopharma or Zymeworks?
Xeris Biopharma (XERS) is larger, with a market capitalization of $1.86B compared with $1.81B for Zymeworks (ZYME).
Which stock has performed better over the past year, XERS or ZYME?
ZYME returned +51.44% over the past 12 months, compared with +24.27% for XERS (price return, excluding dividends). Past performance does not predict future results.
Are Xeris Biopharma and Zymeworks in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.